---
title: "Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285571177.md"
description: "Bank of America Securities analyst Jason Zemansky has maintained a Hold rating on Madrigal Pharmaceuticals (MDGL) with a price target of $550. The analyst, known for a 21.3% average return and a 57.59% success rate, covers the Healthcare sector. The consensus on Madrigal Pharmaceuticals is a Strong Buy, with an average price target of $663.89."
datetime: "2026-05-07T14:01:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285571177.md)
  - [en](https://longbridge.com/en/news/285571177.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285571177.md)
---

# Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Madrigal Pharmaceuticals today and set a price target of $550.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.3% and a 57.59% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Insmed, and Cytokinetics.

Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $663.89.

### Related Stocks

- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [LGND.US](https://longbridge.com/en/quote/LGND.US.md)
- [INSM.US](https://longbridge.com/en/quote/INSM.US.md)
- [CYTK.US](https://longbridge.com/en/quote/CYTK.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)